Smith & Nephew plc (LON:SN)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 9.85B -8.3% |
| Revenue (ttm) | 4.77B +6.0% |
| Net Income | 480.47M +29.3% |
| EPS | 0.56 +31.8% |
| Shares Out | 837.03M |
| PE Ratio | 21.14 |
| Forward PE | 13.87 |
| Dividend | 0.29 (2.49%) |
| Ex-Dividend Date | Oct 1, 2026 |
| Volume | 2,745,390 |
| Open | 1,174.50 |
| Previous Close | 1,169.50 |
| Day's Range | 1,165.00 - 1,181.50 |
| 52-Week Range | 980.40 - 1,396.50 |
| Beta | 0.67 |
| Analysts | Hold |
| Price Target | 1,239.02 (+5.31%) |
| Earnings Date | Mar 1, 2027 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SN stock is "Hold." The 12-month stock price target is 1,239p, which is an increase of 5.31% from the latest price.
News
Smith & Nephew SNATS Q3 Earnings Call Highlights
Smith & Nephew SNATS NYSE: SNN lowered its full-year revenue and trading profit outlook after continued weakness in its U.S. knee and hip businesses tempered otherwise stronger third-quarter growth.
Smith & Nephew price target raised to $33 from $30 at Canaccord
Canaccord raised the firm’s price target on Smith & Nephew to $33 from $30 and keeps a Hold rating on the shares. The firm said they delivered another challenged quarter…
Smith & Nephew Earnings Call Transcript: Q3 2026
Q3 underlying growth accelerated to 3.4%, led by Sports Medicine and ENT, while U.S. Orthopedics remained weak. FY26 revenue growth guidance was reduced to ~3%, with trading profit of ~$1.25bn and free cash flow of ~$750m expected.
Smith & Nephew Slides: Q3 2026
Smith & Nephew has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Smith & Nephew Earnings release: Q3 2026
Smith & Nephew released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Smith & Nephew plc Reports Q3 2026 Revenue of $1,551 million and Revises Full-Year Guidance
Smith & Nephew plc reported its third quarter 2026 trading update, with revenue of $1,551 million compared to $1,501 million in the third quarter of 2025, representing 3.4% revenue growth on both an u...
Smith & Nephew Q3 Revenues Rise, Cuts FY26 Outlook; Continues To Explore Options For Orthopaedics
(RTTNews) - Smith & Nephew Plc (SNN, SN.L), a British medical technology company, reported Wednesday higher revenues in its third quarter, with growth in all regions. Further, the company trimmed fisc...
Smith+Nephew cuts outlook after failed orthopaedics deal talks with J&J
Smith+Nephew cut its full-year revenue and profit forecast on Wednesday as the British medical device maker also confirmed that talks about a potential merger with Johnson & Johnson's (JNJ.N), opens ...
Smith & Nephew price target lowered to 1,380 GBp from 1,550 GBp at Citi
Citi analyst Veronika Dubajova lowered the firm’s price target on Smith & Nephew to 1,380 GBp from 1,550 GBp and keeps a Buy rating on the shares. Published first on…
Smith & Nephew merger talks with J&J orthopaedics unit collapse over CEO role, FT reports
Smith & Nephew's talks with Johnson & Johnson to combine with the US group’s orthopaedics division fell apart after the London-listed group refused to agree to its former CEO leading the merged busine...
Smith & Nephew plc Announces Sterling Dividend Amount of 11.65 Pence per Share
Smith & Nephew plc announced that UK shareholders and those who have validly elected to receive sterling dividends will receive an interim dividend of 11.65 pence per share. As announced on 4 August 2...
Smith & Nephew announces commercial availability of Cartiheal Agili-C in Europe
Smith & Nephew announced that its Cartiheal Agili-C Cartilage Repair Implant is now commercially available in Europe. The Cartiheal Implant will be at this week’s International Cartilage Regeneration ...
Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización ...
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l'innovativo impianto per la riparazione della cartilagine, che sarà presentato all'ICRS Summit in Portogallo.
Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l'innovativo impianto per la riparazione della cartilagine. La tecnologia...
Smith+Nephew's revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CART...
Smith & Nephew removed from European Conviction List at Goldman Sachs
Goldman Sachs analysts removed Smith & Nephew from the firm’s European Conviction List as part of its monthly update.
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
The All-in-one system combines plates, cannulated screws and specialized instrumentation to streamline complex pelvic surgery Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, to...
Smith & Nephew receives 510k clearance from FDA, completes cases with LANDMARK
Smith+Nephew announces it received 510(k) clearance from the U.S. Food and Drug Administration, FDA, and has completed the first surgical cases with LANDMARK Total Knee System. “It is truly a…
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will highlight a suite of advanced solutions for shoulder repair and reconstruction at the International Cong...
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds
Smith+Nephew announces results of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, GB / ACCESS Newswire / September 16, 2026 / Smith+Nephew, the global med...
Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds
Smith+Nephew announces pricing of its cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 15, 2026 / Smith+Nephew, the global med...
Smith & Nephew price target raised to $33.88 from $33.77 at Berenberg
Berenberg raised the firm’s price target on Smith & Nephew to $33.88 from $33.77 and keeps a Hold rating on the shares.
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Smith+Nephew announces cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030 LONDON, UK / ACCESS Newswire / September 8, 2026 / Smith+Nephew, the global medical technology ...
Smith & Nephew downgraded to Neutral from Buy at BofA
BofA downgraded Smith & Nephew to Neutral from Buy with a price target of 1,150 GBp, down from 1,340 GBp. FY26 sales growth guidance was lowered at Q2, notes the…